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Background: Data from retrospective studies have suggested that there may be an interaction between fluco-
nazole and nevirapine, increasing nevirapine concentrations and potentially leading to hepatotoxicity.
Methods: This study was nested within a large double-blind placebo-controlled study designed to determine if
primary prophylaxis with fluconazole (200 mg three times per week) could reduce cryptococcal disease [CRYP-
TOPRO (ISRCTN 76481529)] in HIV-infected adults in rural south-western Uganda. Detailed pharmacokinetic
studies were performed on 49 participants (22 on placebo and 27 on fluconazole) who had been on fluconazole
or placebo with nevirapine for 4 weeks.
Results: The geometric mean pre-dose concentrations of nevirapine were 3865 ng/mL [95% confidence inter-
val (95% CI) 3452–4758 ng/mL] and 5141 ng/mL (95% CI 4760–6595 ng/mL) (P¼0.009) in the placebo and
fluconazole arms, respectively. The change in the peak nevirapine concentration in plasma (Cmax) was also
higher in the fluconazole arm compared with the placebo arm [median 6546 (95% CI 6040–7974) versus
5126 (95% CI 4739–5773) ng/mL, P¼0.012]. Fluconazole increased the nevirapine area under the curve
(AUC) from 0 to 8 h by 29% [geometric mean AUC0–8 46135 (95% CI 42432–57173) versus 35871
(95% CI 32808–41372) ng.h/mL, P¼0.016]. In the larger cohort from which the participants were drawn,
co-administration of fluconazole did not increase the risk of hepatotoxicity.
Conclusions: Fluconazole led to significant increases in nevirapine exposure, but was not associated with
evidence of increased hepatotoxicity.
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Introduction
Fungal infections are a common cause of morbidity and mor-
tality in HIV-infected individuals in sub-Saharan Africa. Flucona-
zole, an azole derivative, is effective against a range of fungal
infections in this setting. It has recently been shown to prevent
cryptococcal disease and mucosal Candida infections in severely
immunosuppressed Ugandan adults.1 Fluconazole is a potent
inhibitor of cytochrome P450 isoenzymes and increases the
plasma concentrations of a number of co-administered drugs,
potentially causing toxicity.2
Nevirapine, a non-nucleoside reverse transcriptase inhibitor,
is a common component of antiretroviral therapy regimens in
sub-Saharan African countries, including Uganda. Nevirapine
undergoes extensive hepatic metabolism into inactive com-
pounds via P450 isoenzymes CYP3A4 and CYP2B6.3 Nevirapine
is associated with severe hepatotoxic reactions and, in some
cases, hepatic failure and death.4 This usually occurs within
the first 6 months after initiation and is associated with
higher CD4 counts, particularly in women. Routine monitoring
of liver function is not recommended in a sub-Saharan
African setting.5
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Data from retrospective studies have suggested that there
may be an interaction between fluconazole and nevirapine,
increasing nevirapine concentrations and potentially leading to
an increase in severe hepatotoxicity.6 This could be particularly
important in sub-Saharan Africa, where access to laboratory
testing and monitoring of drug toxicity is very limited.
There are currently limited data on the interaction of flucona-
zole and nevirapine, and no formal controlled pharmacokinetic
study has ever been performed in HIV-infected individuals. We
examined the interaction between nevirapine and fluconazole or
placebo in 49 HIV-infected Ugandans and relate this to clinical
observations in the cohort from which these patients were drawn.
Methods
Participants
This study was nested within a large double-blind placebo-controlled
study designed to determine if primary prophylaxis with fluconazole
(200 mg three times per week) reduced cryptococcal disease [CRYPTO-
PRO (ISRCTN 76481529)] in rural south-western Uganda.1 Study partici-
pants were antiretroviral-naive adults, with laboratory confirmation of
HIV infection, a CD4 count of ,200 cells/mm3 and a negative cryptococ-
cal antigen test. Exclusion criteria were pregnancy or lactation and aspar-
tate transaminases or alanine transaminases more than three times the
upper limit of normal (ULN). Other liver enzymes were not assayed.
Testing for hepatitis B and hepatitis C viruses was not carried out
unless clinically indicated. Liver function tests were performed on all par-
ticipants every 8 weeks.
Ethics
Information sheets were translated into the local language and written
consent was obtained by trained medical personal. This study received
ethical approval from the institutional review boards of the Uganda
Virus Research Institute and Uganda National Council for Science and
Technology (G/C 127).
Study design
Participants were selected from 1063 individuals taking nevirapine in
CRYPTOPRO by an independent monitor unblinded to trial drug allocation.
All participants had been stable on an antiretroviral regimen containing
200 mg of nevirapine taken twice per day with fluconazole or placebo
for 4 weeks without evidence of hepatotoxicity. Power calculations
were based on data from a previous study and the US Food and Drug
Administration and the European Agency for the Evaluation of Medicinal
Products cut-offs for bioequivalence (80%–125%). Assuming a median
area under the curve from 0 to 12 h (AUC0–12) of 73341 ng.h/mL
(+14818), a sample size of 22 in each group (total sample size 44)
was required to detect a difference of 25% in nevirapine concentrations
with 80% power and 95% confidence.7
Pharmacokinetic studies
Pharmacokinetic studies were performed on 49 participants: 22 (8
female) on placebo and 27 (12 female) on fluconazole. Heparinized
blood (2 mL) was collected via a small-bore canula pre-nevirapine
dosing and at 2, 4 and 8 h after taking antiretroviral therapy. The trial
drug (fluconazole or placebo) was taken at the same time as antiretro-
viral therapy. Plasma was separated for measurement of nevirapine
concentrations and frozen for transport to Liverpool, UK.
Nevirapine concentrations were assayed using validated liquid
chromatography–tandem mass spectrometry (Waters Quattro Premier,
Manchester, UK) with a lower limit of quantification of 450 ng/mL and
inter- and intra-assay variabilities [coefficient of variation (%); using
low, medium and high quality controls] of 11% and 10%, respect-
ively.7 The laboratory participates in an external quality assurance pro-
gramme (KKGT, The Netherlands).
Data analysis
Data were entered into a Microsoftw Access database. The primary
outcome was a change in nevirapine AUC from 0 to 8 h (AUC0–8) and
the secondary outcomes were the nevirapine pre-dose concentration,
the change in peak concentration in plasma (Cmax), the concentration
at 8 h post-dosing (C8) and ‘clearance’ (estimated as dose over 12 h/
AUC0–8). All concentration data were log-transformed to improve
approximation to normality. Non-compartmental analysis was applied
to all the data (WinNonlin v. 5.2) and differences were tested using
unpaired t-tests (Stats Direct).
Results
Participants
The median age was 37 years [interquartile range (IQR) 32–
42 years], 20/49 (41%) were female and the median CD4
count was 52 cells/mm3 (IQR 22–104 cells/mm3). Patients had
been taking fluconazole (27/49) or placebo (22/49) and a
nevirapine-containing antiretroviral regimen for a median of
55 weeks (IQR 48–68 weeks). All were taking two nucleoside
reverse transcriptase inhibitors [10 were on Combivir (lamivudine
and zidovudine), 36 were on stavudine and lamivudine and 3
were on Truvada (tenofovir and emtricitabine)].
Pharmacokinetics
The geometric mean pre-dose concentrations of nevirapine
were 3865 ng/mL [95% confidence interval (95% CI) 3452–
4758 ng/mL] and 5141 ng/mL (95% CI 4760–6595 ng/mL)
(P¼0.009) in the placebo and fluconazole arms, respectively.
Cmax was also higher in the fluconazole arm compared with
0 2 4 6
Time (h)
Pl
as
m
a 
ne
vi
ra
pi
ne
 (n
g/
m
L)
0
2000
4000
6000
8000
10 000
8 10
NVP alone
NVP + FLC
Figure 1. Pharmacokinetic curve of nevirapine (NVP) with and without
fluconazole (FLC). Bars represent 95% confidence intervals.
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the placebo arm [median 6546 (95% CI 6040–7974) versus
5126 (95% CI 4739–5773) ng/mL, P¼0.012]. Fluconazole
increased the nevirapine AUC from 0 to 8 h by 29% [geometric
mean AUC0–8 46135 (95% CI 42432–57173) versus 35871
(95% CI 32808–41372) ng.h/mL, P¼0.016] (Figure 1) and the
concentration at 8 h by 28% from 4023 to 5168 ng/mL
(P¼0.02). Fluconazole also reduced the nevirapine ‘clearance’
from 5.58 (95% CI 5.15–6.34) to 4.34 (95% CI 3.90–5.54) L/h
(P¼0.0172). Gender had no effect upon the nevirapine AUC0–8.
Hepatotoxicity and rash
In the larger cohort from which the participants in this pharma-
cokinetic study were drawn, co-administration of fluconazole did
not increase the risk of hepatotoxicity. One thousand and sixty-
three (81.9%) received an antiretroviral therapy regimen that
contained nevirapine. In those on a nevirapine-containing antire-
troviral regimen, 27/522 (5.2%) and 34/541 (6.3%) taking fluco-
nazole and placebo, respectively, stopped the trial drug due to
elevated transaminases (.5 ULN). None of the 49 participants
had elevated transaminases (.5 ULN) in the first 6–12 weeks
of taking nevirapine and the trial drug (fluconazole or placebo).
In the main study, 14/1063 (1.3%) had liver function tests
.5 ULN in the first 6–12 weeks of nevirapine and the trial
drug. Of the 14, 5 were taking fluconazole and 9 were on
placebo (Fisher’s exact test, P¼0.42). In trial participants
taking nevirapine, 11/522 (2.1%) on fluconazole and 20/541
(3.7%) on placebo had a rash. There was only one case of
Stevens–Johnson syndrome in a patient on fluconazole.
Discussion
Fluconazole is increasingly used as a treatment for cryptococcal
disease or candidiasis in sub-Saharan Africa and recent findings
of its efficacy as prophylaxis against cryptococcal disease may
lead to more widespread use. In this setting, when laboratory
monitoring is limited, establishing its safety is crucial, particularly
when toxicity may be potentially higher due to the high burden
and often additive effects of infection, malignancy or
malnutrition.
There are very limited clinical data on the pharmacokinetic
interaction of azoles and nevirapine. A healthy volunteer study
suggested that co-administration of 200 mg of itraconazole
daily and 200 mg of nevirapine daily did not increase nevirapine
concentrations.8 In contrast, a retrospective Thai study
suggested that co-administration of fluconazole (200 or
400 mg daily) increased mean trough nevirapine concentrations
from 6.5+3.0 mg/L in those not taking fluconazole to 9.8+4.3
and 12.2+6.8 mg/L in those taking it (200 and 400 mg, respect-
ively).9 In our prospective study with controls, we have demon-
strated an almost 30% increase in total exposure (AUC) to
nevirapine when taking fluconazole.
Hepatic toxicity is a serious and potentially life-threatening
complication among HIV-infected individuals who receive nevir-
apine as part of their antiretroviral regimen. Asymptomatic hepa-
titis occurs in 8%–28% of individuals and clinical hepatitis occurs
in 1%–5%.4,10 The rate of severe biochemical hepatotoxicity
(defined as transaminases .5 ULN) in our main cohort was
5.2% and 6.3% in the fluconazole and placebo arms, respect-
ively. Despite the increased exposure of nevirapine in patients
receiving fluconazole, we could find no evidence of a
concentration–toxicity relationship. This may be partially
explained by data suggesting that dose-dependent hepato-
toxicity does not occur until nevirapine concentrations are
.6000–8000 ng/mL.11 In this study, the median Cmax for
those taking fluconazole and nevirapine was 6546 ng/mL. The
lack of increased risk of hepatotoxicity with co-administration
is also in keeping with Thai data that did not detect increased
toxicity, despite increases in trough nevirapine concentrations.9
There are caveats to the interpretation of this study. The dose
of fluconazole used for prophylaxis (200 mg three times per
week) was relatively low and there is a potential for higher treat-
ment doses of 400–800 mg per day to cause even greater
elevations of nevirapine concentrations. The absence of
increased rates of hepatotoxicity in the main study overall does
need to be interpreted in the context that study participants
were at low risk for nevirapine hepatotoxicity with normal trans-
aminases at baseline, had relatively low CD4 cell counts, had
been on nevirapine for a median of 55 weeks and the hepatitis
B and C status of participants was uncertain.4 Nevertheless,
this study clearly demonstrates that despite significant increases
in exposure when nevirapine was co-administered with 200 mg
of fluconazole three times a week, this was not associated
with evidence of hepatotoxicity and gives reassurance for the
use of these two agents together in settings when monitoring
is not available.
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